Salvador University, Brazil.
Metropolitan Union of Education and Culture, Brazil.
Clin Neurol Neurosurg. 2024 Nov;246:108583. doi: 10.1016/j.clineuro.2024.108583. Epub 2024 Oct 4.
Primary brainstem hemorrhage (PBSH) is a fatal condition related to hypertension. PBSH definitive treatment remains controversial, mainly when surgical options are discussed.
To aid decision-making in PBSH scenarios, we aimed to perform a meta-analysis and evaluate the literature on stereotactic aspiration (SA) for PBSH in comparison to conservative management (CM).
The outcomes assessed were: 30-day mortality, mortality, 90-day good outcome (mRs ≤ 3), good outcome (mRs ≤ 3), good outcome (mRs ≤ 3 or GOS 4-5), 90-day poor outcome (mRs ≥ 4), poor outcome (mRs ≥ 4).
We included 1189 patients from 9 studies. 433 (36,41 %) patients were treated with SA. The risk of 30-Day Mortality (RR 0.57; 95 % CI 0.41-0.81; p=0.002; I²=58 %), Mortality (RR 0.56; 95 % CI 0.41-0.75; p<0.001; I²=54 %), 90-Day Poor Outcome (mRS ≥ 4) (RR 0.83; 95 % CI 0.73-0.93; p=0.001; I²=25 %), Poor Outcome (mRS ≥ 4) (RR 0.83; 95 % CI 0.75-0.93; p=0.001; I²=0 %) and Poor Outcome (mRS ≥ 4 or GOS ≤ 3) (RR 0.82; 95 % CI 0.74-0.91; p<0.001; I²=12 %) were significantly lower in patients receiving SA treatment. Also, the risk of 90-Day Good Outcome (mRS ≤ 3) (RR 1.60; 95 % CI 1.06-2.39; p=0.024; I²=21 %), Good Outcome (mRS ≤ 3) (RR 1.48; 95 % CI 1.13-1.94; p=0.005; I²=0) and Good Outcome (mRS ≤ 3 or GOS 4-5) (RR 1.72; 95 % CI 1.17-2.53; p=0.006; I²=25 %) were significant higher in the SA group.
SA demonstrated favorable outcomes, including reduced mortality rates and improved functional recovery. Further clinical trials are needed to validate these findings.
原发性脑干出血(PBSH)是一种与高血压有关的致命疾病。PBSH 的确定性治疗仍存在争议,主要是在讨论手术选择时。
为了帮助 PBSH 情况下的决策制定,我们旨在进行荟萃分析并评估立体定向抽吸(SA)治疗 PBSH 与保守治疗(CM)的文献。
评估的结果包括:30 天死亡率、死亡率、90 天良好结局(mRs ≤ 3)、良好结局(mRs ≤ 3)、良好结局(mRs ≤ 3 或 GOS 4-5)、90 天不良结局(mRs ≥ 4)、不良结局(mRs ≥ 4)。
我们纳入了来自 9 项研究的 1189 名患者。433 名(36.41%)患者接受了 SA 治疗。30 天死亡率(RR 0.57;95%CI 0.41-0.81;p=0.002;I²=58%)、死亡率(RR 0.56;95%CI 0.41-0.75;p<0.001;I²=54%)、90 天不良结局(mRS ≥ 4)(RR 0.83;95%CI 0.73-0.93;p=0.001;I²=25%)、不良结局(mRS ≥ 4)(RR 0.83;95%CI 0.75-0.93;p=0.001;I²=0%)和不良结局(mRS ≥ 4 或 GOS ≤ 3)(RR 0.82;95%CI 0.74-0.91;p<0.001;I²=12%)在接受 SA 治疗的患者中显著降低。此外,接受 SA 治疗的患者 90 天良好结局(mRS ≤ 3)(RR 1.60;95%CI 1.06-2.39;p=0.024;I²=21%)、良好结局(mRS ≤ 3)(RR 1.48;95%CI 1.13-1.94;p=0.005;I²=0%)和良好结局(mRS ≤ 3 或 GOS 4-5)(RR 1.72;95%CI 1.17-2.53;p=0.006;I²=25%)的风险显著升高。
SA 显示出有利的结果,包括降低死亡率和改善功能恢复。需要进一步的临床试验来验证这些发现。